(Total Views: 301)
Posted On: 07/01/2019 11:48:20 AM
Post# of 154959
I don't get why Cydy stated:
"Assays to determine the existence of CCR5 on cancer tissue and the receptor occupancy level for HIV patients are believed to be integral for the effective introduction of leronlimab for therapeutic benefits in this patient population."
Why not?
"Assays to determine the existence of CCR5 on cancer tissue and the receptor occupancy level for HIV patients are believed to be integral for the effective introduction of CCR5 antagonists like leronlimab for therapeutic benefits in this patient population.
Because of this I believe the test involving Leronlimab is only used for possible Leronlimab prescriptions/use cases. Alas.
"Assays to determine the existence of CCR5 on cancer tissue and the receptor occupancy level for HIV patients are believed to be integral for the effective introduction of leronlimab for therapeutic benefits in this patient population."
Why not?
"Assays to determine the existence of CCR5 on cancer tissue and the receptor occupancy level for HIV patients are believed to be integral for the effective introduction of CCR5 antagonists like leronlimab for therapeutic benefits in this patient population.
Because of this I believe the test involving Leronlimab is only used for possible Leronlimab prescriptions/use cases. Alas.
(0)
(0)
